PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447038
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1447038
Alpha Emitter Market Forecasts to 2030 - Global Analysis By Type (Lead, Astatine, Bismuth, Radium, Actinium and Other Types), Source, Application, End User and By Geography
According to Stratistics MRC, the Global Alpha Emitter Market is accounted for $678.4 million in 2023 and is expected to reach $1636.0 million by 2030 growing at a CAGR of 13.4% during the forecast period. An alpha emitter refers to a radioactive substance or isotope that undergoes alpha decay, emitting alpha particles during the process. Alpha particles consist of two protons and two neutrons, essentially equivalent to a helium-4 nucleus. This type of radioactive decay is characterized by the release of alpha particles from the atomic nucleus, resulting in the transformation of the original element into a new element with a lower atomic number. The use of alpha emitters has applications in various fields, including medicine, industry, and research.
According to the International Agency for Research on Cancer (IARC), by 2040, the global burden is projected to increase to 27.5 million active cancer incidents and 16.3 million cancer deaths primarily due to population growth and aging.
Market Dynamics:
Driver:
Rising awareness of alpha particle therapy
The market is experiencing a surge in awareness, particularly driven by the growing recognition of alpha particle therapy. As medical science advances, there is an increasing understanding of the therapeutic potential of alpha emitters in targeted cancer treatments. Alpha particle therapy delivers highly localized and potent radiation, enhancing its efficacy in treating certain types of cancers with minimal damage to surrounding healthy tissues. The rising awareness is likely to propel the demand for alpha emitters, driving further innovations and advancements in this field.
Restraint:
Short half-life of radiopharmaceuticals
The short half-life of radiopharmaceuticals in the market poses a challenge, limiting their effective application in medical and industrial settings. Rapid decay reduces the window of opportunity for administering treatments or conducting experiments, requiring efficient logistics and quick deployment. This constraint may impact the widespread adoption of alpha emitters, especially in scenarios where extended periods of radioactivity are crucial for desired outcomes, necessitating careful consideration of decay rates in planning and implementation.
Opportunity:
Advancements in nuclear medicine
Recent advancements in the market for nuclear medicine have focused on innovative targeted alpha-particle therapies. Alpha emitters exhibit high precision in cancer treatment by delivering localized radiation to tumour cells, minimizing damage to surrounding healthy tissues. These developments enhance the efficacy and safety of therapeutic interventions, marking significant progress in personalized medicine and improving outcomes for patients with certain types of cancer.
Threat:
Need for high capital investment
The market demands substantial capital investment due to the complex and specialized nature of alpha-emitting technologies. Establishing secure production facilities, ensuring compliance with stringent regulatory standards, and investing in advanced research and development for safe applications require significant financial resources. Additionally, the need for extensive safety measures and controlled environments adds to the overall high capital requirements, creating a barrier to entry for potential market participants.
Covid-19 Impact:
The COVID-19 pandemic has influenced the market by disrupting supply chains, delaying research and development projects, and impacting regulatory processes. The increased focus on healthcare during the pandemic has both positively and negatively affected the demand for alpha emitters used in medical applications. While the need for cancer treatments has grown, logistical challenges and prioritization of resources have presented obstacles. The overall market has experienced fluctuations due to the dynamic circumstances created by the global health crisis.
The bismuth segment is expected to be the largest during the forecast period
The bismuth segment is expected to be the largest during the forecast period. It is utilized in targeted alpha-particle radiotherapy for treating certain types of cancer. Its short half-life and ability to deliver high-energy alpha particles make it valuable for precise and effective cancer treatment. The increasing focus on innovative medical therapies has contributed to the growing demand for bismuth-213 and underscores its importance in advancing alpha emitter applications in the medical field.
The ovarian cancer segment is expected to have the highest CAGR during the forecast period
The ovarian cancer segment is expected to have the highest CAGR during the forecast period. This targeted approach minimizes damage to surrounding healthy tissue. However, regulatory approvals, safety considerations, and the need for further clinical evidence may impact their widespread adoption. The evolving landscape of ovarian cancer treatments and research will influence the role of alpha emitters in addressing this challenging disease.
Region with largest share:
North America is projected to hold the largest market share during the forecast period due to increasing applications in medical treatments, particularly in cancer therapy. Growing investments in nuclear power and research and development activities contribute to market expansion. Public perception and regulatory compliance remain pivotal factors influencing the growth of alpha emitters in the region.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period due to increasing applications in medical treatments, research, and nuclear power generation. Rising prevalence of cancer fuels demand for targeted alpha-particle radiotherapy. The region's expanding healthcare sector and research activities contribute to the region's potential, but ongoing developments and adherence to safety protocols will play pivotal roles in shaping the trajectory of the market in this region.
Key players in the market
Some of the key players in Alpha Emitter market include Orano Group, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Novartis International AG, Bayer AG, NorthStar Medical Radioisotopes, Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Ltd, Eckert & Ziegler, RadioMedix, Curium Pharma, Isotopen Technologien Munchen AG (ITM), Nordion Inc..
Key Developments:
In November 2022, IONETIX Corporation, a molecular imaging diagnostics and therapeutics company, announced that the U.S. Nuclear Regulatory Commission (NRC) had issued a Materials License for its new production facility located in Michigan, U.S.
In June 2022, Alpha Tau Medical Ltd., a medical technology company announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational Device Exemption (IDE) application to start its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using Alpha DaRT.
Types Covered:
- Lead
- Astatine
- Bismuth
- Radium
- Actinium
- Other Types
Sources Covered:
- Artificially Produced Sources
- Natural Sources
Applications Covered:
- Prostate Cancer
- Neuroendocrine Tumors
- Bone Metastases
- Ovarian Cancer
- Other Applications
End Users Covered:
- Specialty Clinics
- Diagnostic Centers
- Hospitals
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Researh Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Alpha Emitter Market, By Type
- 5.1 Introduction
- 5.2 Lead
- 5.3 Astatine
- 5.4 Bismuth
- 5.5 Radium
- 5.6 Actinium
- 5.7 Other Types
6 Global Alpha Emitter Market, By Source
- 6.1 Introduction
- 6.2 Artificially Produced Sources
- 6.3 Natural Sources
7 Global Alpha Emitter Market, By Application
- 7.1 Introduction
- 7.2 Prostate Cancer
- 7.3 Neuroendocrine Tumors
- 7.4 Bone Metastases
- 7.5 Ovarian Cancer
- 7.6 Other Applications
8 Global Alpha Emitter Market, By End User
- 8.1 Introduction
- 8.2 Specialty Clinics
- 8.3 Diagnostic Centers
- 8.4 Hospitals
- 8.5 Other End Users
9 Global Alpha Emitter Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Orano Group
- 11.2 Alpha Tau Medical Ltd
- 11.3 Actinium Pharmaceutical Inc.
- 11.4 Novartis International AG
- 11.5 Bayer AG
- 11.6 NorthStar Medical Radioisotopes
- 11.7 Fusion Pharmaceuticals Inc.
- 11.8 Telix Pharmaceuticals Ltd
- 11.9 Eckert & Ziegler
- 11.10 RadioMedix
- 11.11 Curium Pharma
- 11.12 Isotopen Technologien Munchen AG (ITM)
- 11.13 Nordion Inc.
List of Tables
- Table 1 Global Alpha Emitter Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 3 Global Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 4 Global Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 5 Global Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 6 Global Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 7 Global Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 8 Global Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 9 Global Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 10 Global Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 11 Global Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 12 Global Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 13 Global Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 14 Global Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 15 Global Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 16 Global Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 17 Global Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 18 Global Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 19 Global Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 20 Global Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 21 Global Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 22 Global Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 23 North America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
- Table 24 North America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 25 North America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 26 North America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 27 North America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 28 North America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 29 North America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 30 North America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 31 North America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 32 North America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 33 North America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 34 North America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 35 North America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 36 North America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 37 North America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 38 North America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 39 North America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 40 North America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 41 North America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 42 North America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 43 North America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 44 North America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 45 Europe Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
- Table 46 Europe Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 47 Europe Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 48 Europe Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 49 Europe Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 50 Europe Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 51 Europe Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 52 Europe Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 53 Europe Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 54 Europe Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 55 Europe Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 56 Europe Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 57 Europe Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 58 Europe Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 59 Europe Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 60 Europe Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 61 Europe Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 62 Europe Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 63 Europe Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 64 Europe Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 65 Europe Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 66 Europe Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 67 Asia Pacific Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
- Table 68 Asia Pacific Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 69 Asia Pacific Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 70 Asia Pacific Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 71 Asia Pacific Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 72 Asia Pacific Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 73 Asia Pacific Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 74 Asia Pacific Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 75 Asia Pacific Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 76 Asia Pacific Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 77 Asia Pacific Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 78 Asia Pacific Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 79 Asia Pacific Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 80 Asia Pacific Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 81 Asia Pacific Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 82 Asia Pacific Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 83 Asia Pacific Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 84 Asia Pacific Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 85 Asia Pacific Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 86 Asia Pacific Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 87 Asia Pacific Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 88 Asia Pacific Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 89 South America Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
- Table 90 South America Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 91 South America Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 92 South America Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 93 South America Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 94 South America Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 95 South America Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 96 South America Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 97 South America Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 98 South America Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 99 South America Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 100 South America Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 101 South America Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 102 South America Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 103 South America Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 104 South America Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 105 South America Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 106 South America Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 107 South America Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 108 South America Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 109 South America Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 110 South America Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 111 Middle East & Africa Alpha Emitter Market Outlook, By Country (2021-2030) ($MN)
- Table 112 Middle East & Africa Alpha Emitter Market Outlook, By Type (2021-2030) ($MN)
- Table 113 Middle East & Africa Alpha Emitter Market Outlook, By Lead (2021-2030) ($MN)
- Table 114 Middle East & Africa Alpha Emitter Market Outlook, By Astatine (2021-2030) ($MN)
- Table 115 Middle East & Africa Alpha Emitter Market Outlook, By Bismuth (2021-2030) ($MN)
- Table 116 Middle East & Africa Alpha Emitter Market Outlook, By Radium (2021-2030) ($MN)
- Table 117 Middle East & Africa Alpha Emitter Market Outlook, By Actinium (2021-2030) ($MN)
- Table 118 Middle East & Africa Alpha Emitter Market Outlook, By Other Types (2021-2030) ($MN)
- Table 119 Middle East & Africa Alpha Emitter Market Outlook, By Source (2021-2030) ($MN)
- Table 120 Middle East & Africa Alpha Emitter Market Outlook, By Artificially Produced Sources (2021-2030) ($MN)
- Table 121 Middle East & Africa Alpha Emitter Market Outlook, By Natural Sources (2021-2030) ($MN)
- Table 122 Middle East & Africa Alpha Emitter Market Outlook, By Application (2021-2030) ($MN)
- Table 123 Middle East & Africa Alpha Emitter Market Outlook, By Prostate Cancer (2021-2030) ($MN)
- Table 124 Middle East & Africa Alpha Emitter Market Outlook, By Neuroendocrine Tumors (2021-2030) ($MN)
- Table 125 Middle East & Africa Alpha Emitter Market Outlook, By Bone Metastases (2021-2030) ($MN)
- Table 126 Middle East & Africa Alpha Emitter Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
- Table 127 Middle East & Africa Alpha Emitter Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 128 Middle East & Africa Alpha Emitter Market Outlook, By End User (2021-2030) ($MN)
- Table 129 Middle East & Africa Alpha Emitter Market Outlook, By Specialty Clinics (2021-2030) ($MN)
- Table 130 Middle East & Africa Alpha Emitter Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
- Table 131 Middle East & Africa Alpha Emitter Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 132 Middle East & Africa Alpha Emitter Market Outlook, By Other End Users (2021-2030) ($MN)
